| The following article features coverage from the IASLC 18th World Conference on Lung Cancer (WCLC) in Yokohama, Japan. Click here to read more of Cancer Therapy Advisor‘s conference coverage. |
An updated analysis of the KEYNOTE-024 (ClinicalTrials.gov Identifier: NCT02142738) study showed that pembrolizumab monotherapy maintained superiority compared with platinum-based chemotherapy and nearly doubled overall survival (OS) among patients with advanced non–small cell lung cancer (NSCLC), according to a presentation at the International Association for the Study of Lung Cancer (IASLC) 18th Annual World Conference on Lung Cancer (WCLC) in Yokohama, Japan.1
For the phase 3 KEYNOTE-024 study, researchers randomly assigned 305 patients with advanced NSCLC of any histological type to 35 cycles of pembrolizumab or 4 to 6 cycles of investigator’s choice chemotherapy. Eligible patients did not have EGFR mutations or ALK translocations and had a PD-L1 tumor proportion score of 50% or greater.
Continue Reading
The median follow-up period for the current analysis was 25.2 months. Patients in the pembrolizumab arm had a median OS of 30.0 months (95% CI, 18.3-not reached) compared with 14.2 months (95% CI, 9.8-19.0) among patients in the chemotherapy arm. A Kaplan-Meier estimate of OS at 12 months was 70.3% (95% CI, 62.3%-76.9%) and 54.8% (95% CI, 46.4%-62.4%) for the pembrolizumab arm and chemotherapy arm, respectively.
At time of follow-up, 47.4% and 63.6% of patients in the pembrolizumab arm and chemotherapy arm had died, respectively. Eighty-two patients enrolled in the chemotherapy arm crossed over once meeting eligibility criteria for the pembrolizumab arm.
Patients in the pembrolizumab arm had lower rates of grade 3 to 5 adverse events (AEs) compared with those in the chemotherapy arm (31.2% vs 53.3%, respectively), as well as a lower rate of overall AEs (76.6% vs 90.0%, respectively).
Read more of Cancer Therapy Advisor‘s coverage of the IASLC 18th World Conference on Lung Cancer (WCLC) by visiting the conference page.
Reference
- Brahmer JR, Rodriguez-Abreu D, Robinson A, et al. Updated analysis of KEYNOTE-024: pembrolizumab vs platinum-based chemotherapy for advanced NSCLC with PD-L1 TPS>50%. Presented at: International Association for the Study of Lung Cancer 18th World Conference on Lung Cancer; Yokohama, Japan: October 15-18, 2017. Abstract OA 17.06.
